ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2029

Improved Provider Awareness and Delivery of Zoster Vaccination in Patients with Rheumatoid Arthritis Contemplating Biologic Therapy: Need to Target Eligible Patients Prescribed for Vaccination Post-Clinic

Gina Prakash1, Kenneth O'Rourke2 and Stephen Mullis3, 1Department of Internal medicine, Section on Rheumatology and Immunology, Wake Forest School of Medicine, Winston Salem, NC, 2Department of Internal Medicine, Section on Rheumatology and Immunology, Wake Forest School of Medicine, Winston-Salem, NC, 3Department of Internal Medicine, Section on Rheumatology and Immunology, Wake Forest School of Medicine, Winston Salem, NC

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Biologic agents, rheumatoid arthritis (RA) and vaccines

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Measures and Measurement of Healthcare Quality Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Vaccination against herpes zoster (shingles) can reduce the frequency of infection, the severity of shingles should it occur, and the frequency of post-herpetic neuralgia. As active biologic therapy is currently considered a contraindication to vaccination against shingles with a live virus zoster vaccine (LVZV), provider awareness of this situation may promote vaccination rates in eligible patients for whom biologic therapy is contemplated. Factors such as determining vaccine cost may limit point-of-care (POC) vaccination in eligible patients.

Methods:

In patients with a coded diagnosis of rheumatoid arthritis (RA) chart documentation assessed how frequently LVZV was addressed prior to initiation of biologic therapy. Following an educational intervention, a reminder and documentation system was implemented using a sheet given to all patients at the time of clinic intake, including a decision tree for providers to determine the need for vaccination based on age, prior vaccine status, diagnosis, and potential contraindications. A senior rheumatology fellow reviewed all charts. Pre-intervention consecutive charts from patients attending the rheumatology outpatient clinics in 2016 from 5/1 thru 5/31 were retrospectively reviewed. Inclusion criteria were patients coded with RA, age >50 years, and on biologic therapy. Exclusion criteria included patients already on biologics prior to established care in our clinic, or contraindication to LVZV per CDC guidelines. The post-intervention study prospectively reviewed charts on the same eligible consecutive patients seen in 2017 from 5/10 thru 5/26.

Results:

Of 168 consecutive charts retrospectively reviewed pre-intervention, only 76 met eligibility criteria. In 0 charts was there provider documentation about the need for vaccination. Although nursing and/or medication documentation noted LVZV was appropriately given in 19%, there was no provider documentation as to why or if it actually was given. The percentage of vaccinated patients being seen solely by attendings were slightly higher compared to those seen by fellows.

All patients representing the 116 consecutive charts, which were reviewed post-intervention, were screened with the reminder sheet: only 16 met eligibility criteria for LVZV. Only 2 of the eligible patients received LVZV or a prescription for it accompanied by documentation by the provider in the record that the vaccine was given. 8 of the eligible patients were given a prescription for LVZV vaccination (4 seen by attendings, 4 by fellows), but there has been no documentation of the provider subsequently receiving confirmation that patients so prescribed actually received the vaccine. 6 of the eligible patients already had received LVZV previously as recorded in the clinic reminder sheet, but in only 4 patients was subsequent chart documentation found.

Conclusion:

In eligible RA patients the documentation of completed LVZV remains low. The majority of eligible patients required a prescription for vaccination after POC, but there has been no confirmation that any received it. Efforts at increasing vaccination rates should be directed at providing a system to report back successful receipt of vaccination post-visit.


Disclosure: G. Prakash, None; K. O'Rourke, ACR Curriculum Subcommittee, 6; S. Mullis, None.

To cite this abstract in AMA style:

Prakash G, O'Rourke K, Mullis S. Improved Provider Awareness and Delivery of Zoster Vaccination in Patients with Rheumatoid Arthritis Contemplating Biologic Therapy: Need to Target Eligible Patients Prescribed for Vaccination Post-Clinic [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/improved-provider-awareness-and-delivery-of-zoster-vaccination-in-patients-with-rheumatoid-arthritis-contemplating-biologic-therapy-need-to-target-eligible-patients-prescribed-for-vaccination-post-cl/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improved-provider-awareness-and-delivery-of-zoster-vaccination-in-patients-with-rheumatoid-arthritis-contemplating-biologic-therapy-need-to-target-eligible-patients-prescribed-for-vaccination-post-cl/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology